Dopamine treatment and cognitive functioning in individuals with Parkinson's disease: the "cognitive flexibility" hypothesis seems to work

Alberto Costa, Antonella Peppe, Ilenia Mazzù, Mariachiara Longarzo, Carlo Caltagirone, Giovanni A Carlesimo, Alberto Costa, Antonella Peppe, Ilenia Mazzù, Mariachiara Longarzo, Carlo Caltagirone, Giovanni A Carlesimo

Abstract

Background: Previous data suggest that (i) dopamine modulates the ability to implement nonroutine schemata and update operations (flexibility processes) and that (ii) dopamine-related improvement may be related to baseline dopamine levels in target pathways (inverted U-shaped hypothesis).

Objective: To investigate above hypotheses in individuals with Parkinson's disease (PD).

Methods: Twenty PD patients were administered tasks varying as to flexibility load in two treatment conditions: (i) "off" condition, about 18 hours after dopamine dose and (ii) "on" condition, after dopamine administration. PD patients were separated into two groups: low performers (i.e., performance on Digit Span Backward below the sample mean) and high performers (i.e., performance above the mean). Twenty healthy individuals performed the tasks in two sessions without taking drugs.

Results: Passing from the "off" to the "on" state, only low performer PD patients significantly improved their performance on high-flexibility measures (interference condition of the Stroop test; P < 0.05); no significant effect was found on low-flexibility tasks.

Conclusions: These findings document that high-flexibility processes are sensitive to dopamine neuromodulation in the early phases of PD. This is in line with the hypothesis that striatal dopamine pathways, affected early by PD, are precociously implicated in the expression of cognitive disorders in these individuals.

Figures

Figure 1
Figure 1
Average performance on Stroop subtests of individuals in the four experimental groups. Accuracy (a) and response times (b) are reported.
Figure 2
Figure 2
Average performance on fluency subtests of individuals in the four experimental groups on fluency subtests.

References

    1. Cools R, D’Esposito M. Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biological Psychiatry. 2011;69(12):e113–e125.
    1. Cools R, Sheridan M, Jacobs E, D’Esposito M. Impulsive personality predicts dopamine-dependent changes in frontostriatal activity during component processes of working memory. The Journal of Neuroscience. 2007;27(20):5506–5514.
    1. Kimberg DY, D’Esposito M, Farah MJ. Effects of bromocriptine on human subjects depend on working memory capacity. NeuroReport. 1997;8(16):3581–3585.
    1. Mehta MA, Swainson R, Ogilvie AD, Sahakian B, Robbins TW. Improved short-term spatial memory but impaired reversal learning following the dopamine D2 agonist bromocriptine in human volunteers. Psychopharmacology. 2001;159(1):10–20.
    1. Mehta MA, Manes FF, Magnolfi G, Sahakian BJ, Robbins TW. Impaired set-shifting and dissociable effects on tests of spatial working memory following the dopamine D2 receptor antagonist sulpiride in human volunteers. Psychopharmacology. 2004;176(3-4):331–342.
    1. Cools R. Dopaminergic control of the striatum for high-level cognition. Current Opinion in Neurobiology. 2011;21(3):1–6.
    1. Owen AM. Cognitive dysfunction in Parkinson’s disease: the role of frontostriatal circuitry. Neuroscientist. 2004;10(6):525–537.
    1. Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson’s disease. Neuroscience and Biobehavioral Reviews. 2006;30(1):1–23.
    1. Fallon SJ, Williams-Gray CH, Barker RA, Owen AM, Hampshire A. Prefrontal dopamine levels determine the balance between cognitive stability and flexibility. Cerebral Cortex. 2013;23(2):361–369.
    1. Frank MJ, Fossella JA. Neurogenetics and pharmacology of learning, motivation, and cognition. Neuropsychopharmacology. 2011;36(1):133–152.
    1. Crofts HS, Dalley JW, Collins P, et al. Differential effects of 6-OHDA lesions of the frontal cortex and caudate nucleus on the ability to acquire an attentional set. Cerebral Cortex. 2001;11(11):1015–1026.
    1. Roberts AC, de Salvia MA, Wilkinson LS, et al. 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin card sort test: possible interactions with subcortical dopamine. The Journal of Neuroscience. 1994;14(5 I):2531–2544.
    1. Gotham AM, Brown RG, Marsden CD. ‘Frontal’ cognitive function in patients with Parkinson’s disease “on” and “off” levodopa. Brain. 1988;111(part 2):299–321.
    1. Agid Y, Ruberg M, Javoy-Agid F, et al. Are dopaminergic neurons selectively vulnerable to Parkinson’s disease? Advances in Neurology. 1993;60:148–164.
    1. Yeterian EH, Pandya DN. Prefrontostriatal connections in relation to cortical architectonic organization in rhesus monkeys. Journal of Comparative Neurology. 1991;312(1):43–67.
    1. Costa A, Peppe A, Dell’Agnello G, Caltagirone C, Carlesimo GA. Dopamine and cognitive functioning in de novo subjects with Parkinson’s disease: effects of pramipexole and pergolide on working memory. Neuropsychologia. 2009;47(5):1374–1381.
    1. Costa A, Peppe A, Dell’Agnello G, et al. Dopaminergic modulation of visual-spatial working memory in Parkinson’s disease. Dementia and Geriatric Cognitive Disorders. 2003;15(2):55–66.
    1. Costa A, Peppe A, Brusa L, Caltagirone C, Gatto I, Carlesimo GA. Levodopa improves time-based prospective memory in Parkinson’s disease. Journal of the International Neuropsychological Society. 2008;14(4):601–610.
    1. Kimberg DY, D’Esposito M. Cognitive effects of the dopamine receptor agonist pergolide. Neuropsychologia. 2003;41(8):1020–1027.
    1. Cohen JD, Braver TS, Brown JW. Computational perspectives on dopamine function in prefrontal cortex. Current Opinion in Neurobiology. 2002;12(2):223–229.
    1. Frank MJ. Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated Parkinsonism. Journal of Cognitive Neuroscience. 2005;17(1):51–72.
    1. Frank MJ, Loughry B, O’Reilly RC. Interactions between frontal cortex and basal ganglia in working memory: a computational model. Cognitive, Affective and Behavioral Neuroscience. 2001;1(2):137–160.
    1. Camps M, Kelly PH, Palacios JM. Autoradiographic localization of dopamine D1 and D2 receptors in the brain of several mammalian species. Journal of Neural Transmission. 1990;80(2):105–127.
    1. Crofts HS, Dalley JW, Collins P, et al. Parkinson's disease: mechanism and models. Neuron. 2003;39:889–909.
    1. Collins P, Wilkinson LS, Everitt BJ, Robbins TW, Roberts AC. The effect of dopamine depletion from the caudate nucleus of the common marmoset (Callithrix jacchus) on tests of prefrontal cognitive function. Behavioral Neuroscience. 2000;114(1):3–17.
    1. MacDonald PA, Monchi O. Differential effects of dopaminergic therapies on dorsal and ventral striatum in Parkinson’s disease: implications for cognitive function. Parkinson’s Disease. 2011;2011:6 pages.572743
    1. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. The Lancet Neurology. 2010;9(12):1200–1213.
    1. Kliegel M, Altgassen M, Hering A, Rose NS. A process-model based approach to prospective memory impairment in Parkinson’s disease. Neuropsychologia. 2011;49(8):2166–2177.
    1. Cools R, Barker RA, Sahakian BJ, Robbins TW. L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson’s disease. Neuropsychologia. 2003;41(11):1431–1441.
    1. Cools R, Miyakawa A, Sheridan M, D’Esposito M. Enhanced frontal function in Parkinson’s disease. Brain. 2010;133(part 1):225–233.
    1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. Journal of Neurology Neurosurgery and Psychiatry. 1992;55(3):181–184.
    1. Folstein MF, Folstein SE, McHugh PR. ‘Mini mental state’. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12(3):189–198.
    1. Measso G, Cavarzeran F, Zappala G, et al. The Mini Mental State examination: normative study of a random sample of the Italian population. Developmental Neuropsychology. 1991;9:77–85.
    1. Fahn S, Elton RL. Unified Parkinson's disease rating scale. In: Fahn S, Marsden PD, Calne DB, Lieberman A, editors. Recent Developments in Parkinson's Disease. Florham Park, NJ, USA: Macmillan Health Care Information; 1987. pp. 153–163.
    1. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Movement Disorders. 2010;25(15):2649–2653.
    1. Carlesimo GA, Caltagirone C, Gainotti G. The mental deterioration battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. European Neurology. 1996;36(6):378–384.
    1. Carlesimo GA, Buccione I, Fadda L, et al. Standardizzazione di due test di memoria per uso clinico: breve racconto e figura di Rey. Nuova Rivista di Neurologia. 2002;12:1–13.
    1. Monaco M, Costa A, Caltagirone C, Carlesimo GA. Forward and backward span for verbal and visuo-spatial data: standardization and normative data from an Italian adult population. Neurological Sciences. 2013;34(5):749–754.
    1. Nocentini U, Di Vincenzo S, Panella M, Pasqualetti P, Caltagirone C. La valutazione delle funzioni esecutive nella pratica neuropsicologica, dal Modified Card Sorting Test al Modified Card Sorting Test-Roma Version. Dati di standardizzazione. Nuova Rivista di Neurologia. 2002;12(1):13–24.
    1. de Bleser R, Denes G, Luzzatti C, et al. L'Aachener Aphasie test I: problemi e soluzioni per una versione italiana del test e per uno studio crosslinguistico dei disturbi afasici. Archivio di Psicologia, Neurologia e Psichiatria. 1986;47:209–236.
    1. Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT) Movement Disorders. 1992;7(1):2–13.
    1. Golden C. Stroop Color and Word Test. Manual. Chicago, Ill, USA: Stoelting; 1978.
    1. Jurado MB, Rosselli M. The elusive nature of executive functions: a review of our current understanding. Neuropsychology Review. 2007;17(3):213–233.
    1. Spinnler H, Tognoni G. Standardizzazione e taratura italiana di test neuropsicologici. The Italian Journal of Neurological Sciences. 1987;8(supplement):1–20.
    1. Downes JJ, Sharp HM, Costall BM, Sagar HJ, Howe J. Alternating fluency in Parkinson’s disease. An evaluation of the attentional control theory of cognitive impairment. Brain. 1993;116(part 4):887–902.
    1. Henry JD, Crawford JR. Verbal fluency deficits in Parkinson’s disease: a meta-analysis. Journal of the International Neuropsychological Society. 2004;10(4):608–622.
    1. Blonder LX, Slevin JT. Emotional dysfunction in Parkinson’s disease. Behavioural Neurology. 2011;24(3):201–217.
    1. Costa A, Peppe A, Carlesimo GA, Pasqualetti P, Caltagirone C. Major and minor depression in Parkinson’s disease: a neuropsychological investigation. European Journal of Neurology. 2006;13(9):972–980.
    1. Santangelo G, Vitale C, Trojano L, et al. Relationship between depression and cognitive dysfunctions in Parkinson′s disease without dementia. Journal of Neurology. 2009;256(4):632–638.
    1. Spielberg CD. Manual for the State-Trait Anxiety Inventory. Palo Alto, Calif, USA: Consulting Psychologists Press; 1983.
    1. Beck AT, Steer RA. Beck Depression Inventory Manual. San Antonio, Tex, USA: Psychological Corporation; 1987.
    1. Visser M, Leentjens AFG, Marinus J, Stiggelbout AM, van Hilten JJ. Reliability and validity of the Beck Depression Inventory in patients with Parkinson’s disease. Movement Disorders. 2006;21(5):668–672.
    1. Egner T, Hirsch J. Cognitive control mechanisms resolve conflict through cortical amplification of task-relevant information. Nature Neuroscience. 2005;8(12):1784–1790.
    1. Miyake A, Friedman NP, Emerson MJ, Witzki AH, Howerter A, Wager TD. The unity and diversity of executive functions and their contributions to complex, “Frontal Lobe” tasks: a latent variable analysis. Cognitive Psychology. 2000;41(1):49–100.
    1. Koch G, Costa A, Brusa L, et al. Impaired reproduction of second but not millisecond time intervals in Parkinson’s disease. Neuropsychologia. 2008;46(5):1305–1313.
    1. Lewis SJG, Slabosz A, Robbins TW, Barker RA, Owen AM. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson’s disease. Neuropsychologia. 2005;43(6):823–832.
    1. MacDonald PA, MacDonald AA, Seergobin KN, et al. The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson’s disease: support from functional MRI. Brain. 2011;134(part 5):1447–1463.
    1. Cai X, Kim S, Lee D. Heterogeneous coding of temporally discounted values in the dorsal and ventral striatum during intertemporal choice. Neuron. 2011;69(1):170–182.
    1. Ding L, Gold JI. Caudate encodes multiple computations for perceptual decisions. The Journal of Neuroscience. 2010;30(47):15747–15759.
    1. Cohen JD, Botvinick M, Carter CS. Anterior cingulate and prefrontal cortex: who’s in control? Nature Neuroscience. 2000;3(5):421–423.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe